Moretta A, Bottino C, Pende D, Tripodi G, Tambussi G, Viale O, Orengo A, Barbaresi M, Merli A, Ciccone E
Istituto di Istologia ed Embriologia Generale, Universitá di Genova, Italy.
J Exp Med. 1990 Dec 1;172(6):1589-98. doi: 10.1084/jem.172.6.1589.
In previous studies we identified a surface molecule (termed GL183) capable of mediating cell activation and selectively expressed by a subset of human CD3-CD16+ natural killer (NK) cells. In this study we analyzed whether other subset-specific functional molecules were expressed in GL183- NK cells. To this end, mice were immunized with the PE29 (CD3-CD16+GL183-) NK clone. Monoclonal antibodies (mAbs) were selected by screening the hybridoma supernatants for their ability to trigger the cytolytic activity of clone PE29 against the human myelomonocytic leukemia U937. The EB6 mAb (IgG1) triggered the PE29 clone, but not a GL183+ clone used as a control. EB6+ cells ranged between 1 and 13% of peripheral blood lymphocytes and were largely included in the CD3-CD16+CD56+ cell populations (only less than 2% of EB6+ cells were CD3+). Analysis of resting or activated CD3-CD16+ populations, or clones for the expression of EB6 or GL183 mAbs, allowed us to identify four distinct, phenotypically stable, NK subsets (EB6+GL183-; EB6+GL183+; EB6-GL183+; EB6-GL183-). Similar to GL183 mAb, the EB6 mAb selectively triggered the NK subset expressing the corresponding surface antigen to lyse human tumor cell lines including U937, IGROV-I, M14, and A549. In addition, EB6 mAb sharply inhibited the cytolytic activity of EB6+ clones against P815, M12, and P3U1 murine target cells. In EB6+GL183+ ("double-positive") clones both EB6 and GL183 mAb inhibited the redirected killing of P815 cells induced by anti-CD16, anti-CD2 mAbs and phytohemagglutinin (PHA). Similar to GL183 molecules, molecules precipitated by EB6 mAb were represented by either single 58-kD chain or double chains of 55 and 58 kD (with no detectable differences in EB6+GL183- or EB6+GL183+ clones). In sequential immunoprecipitation experiments using the double-positive clones CEG52 and CA25.50, preclearing of cell lysates with EB6 or GL183 mAb removed only EB6 or GL183 molecules, respectively, thus indicating that the two antigenic determinants are carried by two distinct molecules. Peptide map analysis indicated that EB6 (or GL183) molecules precipitated from double-positive clones were identical to the corresponding molecules isolated from single-positive ones. On the other hand, comparison of the EB6 and GL183 maps revealed peptides that were unique to each molecule, although most of the major peptides migrated to identical positions. We further investigated whether correlation existed between the phenotypic assignment of NK clones and their ability to mediate specific lysis of normal allogeneic cells.(ABSTRACT TRUNCATED AT 400 WORDS)
在先前的研究中,我们鉴定出一种能够介导细胞活化的表面分子(称为GL183),它由一部分人类CD3 - CD16 + 自然杀伤(NK)细胞选择性表达。在本研究中,我们分析了GL183 - NK细胞中是否表达其他亚群特异性功能分子。为此,用PE29(CD3 - CD16 + GL183 - )NK克隆免疫小鼠。通过筛选杂交瘤上清液触发克隆PE29对人骨髓单核细胞白血病U937的细胞溶解活性的能力来选择单克隆抗体(mAb)。EB6单克隆抗体(IgG1)触发了PE29克隆,但未触发用作对照的GL183 + 克隆。EB6 + 细胞在外周血淋巴细胞中占1%至13%,并且大部分包含在CD3 - CD16 + CD56 + 细胞群体中(只有不到2%的EB6 + 细胞是CD3 + )。对静息或活化的CD3 - CD16 + 群体或克隆进行EB6或GL183单克隆抗体表达分析,使我们能够鉴定出四个不同的、表型稳定的NK亚群(EB6 + GL183 - ;EB6 + GL183 + ;EB6 - GL183 + ;EB6 - GL183 - )。与GL183单克隆抗体类似,EB6单克隆抗体选择性地触发表达相应表面抗原的NK亚群裂解包括U937、IGROV - I、M14和A549在内的人肿瘤细胞系。此外,EB6单克隆抗体显著抑制EB6 + 克隆对P815、M12和P3U1小鼠靶细胞的细胞溶解活性。在EB6 + GL183 + (“双阳性”)克隆中,EB6和GL183单克隆抗体均抑制抗CD16、抗CD2单克隆抗体和植物血凝素(PHA)诱导的P815细胞的重定向杀伤。与GL183分子类似,EB6单克隆抗体沉淀的分子由单条58 - kD链或55和58 kD的双链组成(在EB6 + GL183 - 或EB6 + GL183 + 克隆中未检测到差异)。在使用双阳性克隆CEG52和CA25.50的连续免疫沉淀实验中,用EB6或GL183单克隆抗体预先清除细胞裂解物分别仅去除EB6或GL183分子,因此表明这两个抗原决定簇由两个不同的分子携带。肽图谱分析表明,从双阳性克隆中沉淀的EB6(或GL183)分子与从单阳性克隆中分离的相应分子相同。另一方面,EB6和GL183图谱的比较揭示了每个分子特有的肽段,尽管大多数主要肽段迁移到相同位置。我们进一步研究了NK克隆的表型分类与其介导正常同种异体细胞特异性裂解能力之间是否存在相关性。(摘要截断于400字)